Welcome to “Minds Behind the Science,” a series dedicated to celebrating the achievements of physicians, researchers, and healthcare professionals. At Organon, we believe in the power of diverse voices and perspectives to help drive innovation and improve health outcomes. Through this series, we will highlight the inspiring stories that are driving the people of Organon […]
– 46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (P<0.0001) – – All secondary endpoints were met with a high degree of statistical significance, including 59.1% of subjects treated with VTAMA cream who achieved the key secondary endpoint of EASI75 (P<0.0001) – – Meaningful impact on the key secondary endpoint of pruritus (itch) was demonstrated with 52.8% of subjects ≥12 years old, with a baseline PP-NRS score ≥4, achieving a ≥4-point reduction in the PP-NRS at Week 8 (P=0.0015) – – Rollover rate of 92.4% of Phase 3 subjects from this trial into the open-label, long-term safety study* – – Conference call and webcast on March 15, 2023 at 8:00 a.m. ET – LONG BEACH, Calif., and BASEL, Switzerland, March 15, 2023 – Dermavant Sciences, a
Organon Proposed Board of Directors To Have More Women Than Any S&P 500 Healthcare Company Investor Day Planned for May 3 Ahead of Spinoff in Late Second Quarter 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission (“SEC”) in connection with the intended spinoff of its women’s health, biosimilars and established brands businesses into a standalone, publicly-traded company, Organon. Organon will register its common stock under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”). The Form 10 includes detailed information about Organon, such as historic financial information, as well as a description of Organon’s business and strategy and other legal and financial disclosures. A copy of the Form 10 is available on the SEC website at www.sec.gov and can also be viewed on www.merck.com/investors/sec-filings . Completion of
Alan Ezekowitz Alan Ezekowitz, M.D., D. Phil., is currently a venture partner at Third Rock Ventures, LLC, a healthcare venture firm, an Entrepreneur in Residence at Cardinal Partners, a venture capital firm, an adviser to Fidelity’s Select Biotechnology Portfolio, and as a consultant to H. Lundbeck A/S. From 2011 to 2019, Dr. Ezekowitz was Co-Founder […]
